Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses

2020-08-24T09:48:37-04:00August 24th, 2020|Press Release|

Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections Virpax Pharmaceuticals Inc. (“Virpax”), today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density [...]

Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on NES100 for the Management of Acute and Chronic Pain

2020-03-01T14:50:40-05:00March 2nd, 2020|Press Release|

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems today announced that it has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food [...]

Virpax Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition

2020-02-24T01:26:45-05:00February 5th, 2020|Press Release|

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2020 Special Operations Medical Association’s Training, Education, Scientific Assembly [...]

Go to Top